Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Nathalia A. Giese

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5920-3142; OpenAlex author ID A5044899355. Sources: OpenAlex.

Their work

Papers
61 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
173
Papers, trials and grants by year

2011: 5 papers · 2012: 7 papers · 2013: 7 papers · 2014: 6 papers · 2015: 5 papers · 2016: 6 papers · 2017: 3 papers · 2018: 4 papers · 2019: none · 2020: 2 papers · 2021: 6 papers · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 50 of 61

  1. Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. Co-author DOI 10.1097/mpa.0000000000002553↗
  2. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  3. Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Co-author DOI 10.1038/s41419-023-06385-9↗
  4. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.28527↗
  5. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  6. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma. Co-author DOI 10.1136/gutjnl-2023-330155↗
  7. Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers15061815↗
  8. Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2027148↗
  9. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. Co-author DOI 10.1186/s13046-022-02519-7↗
  10. Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.947407↗
  11. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. Co-author DOI 10.1016/j.ctrv.2021.102193↗
  12. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic… Co-author DOI 10.1080/2162402x.2021.1962135↗
  13. Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer Co-author DOI 10.1101/2021.03.13.435100↗
  14. Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids Co-author DOI 10.1101/2021.08.26.457743↗
  15. Promoter Hypermethylation Promotes the Binding of Transcription Factor NFATc1, Triggering Oncogenic Gene Activation in Pancreatic Cancer. Co-author DOI 10.3390/cancers13184569↗
  16. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer. Last author DOI 10.3390/v13061019↗
  17. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis. Co-author DOI 10.1002/1878-0261.12684↗
  18. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  19. Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. Co-author DOI 10.1002/ijc.31087↗
  20. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0036↗
  21. Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24312↗
  22. Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. First author DOI 10.7150/jca.21803↗
  23. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  24. Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.14449↗
  25. HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study. Co-author DOI 10.18632/oncotarget.18757↗
  26. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.30291↗
  27. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
  28. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Co-author DOI 10.1053/j.gastro.2016.08.040↗
  29. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  30. PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulator… Co-author DOI 10.1158/0008-5472.can-15-0216↗
  31. Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-15-0390↗
  32. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Co-author DOI 10.1002/ijc.29324↗
  33. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  34. Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Co-author DOI 10.1016/j.canlet.2014.12.037↗
  35. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Co-author DOI 10.1038/nm.3957↗
  36. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3171↗
  37. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Co-author DOI 10.1002/ijc.28597↗
  38. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  39. Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Co-author DOI 10.1093/carcin/bgt394↗
  40. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. Last author DOI 10.1128/jvi.03688-13↗
  41. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. First author DOI 10.1158/1078-0432.ccr-13-2972↗
  42. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Co-author DOI 10.18632/oncotarget.1764↗
  43. Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells. Co-author DOI 10.1002/ijc.28044↗
  44. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  45. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Co-author DOI 10.1038/cddis.2013.158↗
  46. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  47. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1371/journal.pone.0060529↗
  48. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0067059↗
  49. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗
  50. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.26502↗

Closest collaborators

The 25 strongest of 173 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 26 shared papers, 2012–2026 · strength 2.65
  2. Markus Wolfgang Büchler · 19 shared papers, 2011–2025 · strength 1.38
  3. Oliver Strobel · 16 shared papers, 2015–2024 · strength 1.20
  4. Jörg D. Hoheisel · 13 shared papers, 2011–2023 · strength 0.88
  5. Andrea S. Bauer · 12 shared papers, 2011–2023 · strength 0.87
  6. Christoph Springfeld · 6 shared papers, 2018–2023 · strength 0.80
  7. Niels Halama · 5 shared papers, 2021–2023 · strength 0.74
  8. Azaz Ahmed · 5 shared papers, 2021–2023 · strength 0.74
  9. Rosa Klotz · 5 shared papers, 2021–2023 · strength 0.74
  10. Miriam Schenk · 5 shared papers, 2015–2025 · strength 0.64
  11. Ingrid Herr · 5 shared papers, 2013–2024 · strength 0.50
  12. Matthias M. Gaida · 8 shared papers, 2011–2021 · strength 0.44
  13. Aldo Scarpa · 6 shared papers, 2013–2025 · strength 0.43
  14. Jens Werner · 14 shared papers, 2011–2016 · strength 0.42
  15. Yenan Wu · 3 shared papers, 2020–2023 · strength 0.40
  16. Fawaz N. Al-Shaheri · 2 shared papers, 2021–2023 · strength 0.31
  17. Svitlana P. Grekova · 5 shared papers, 2011–2021 · strength 0.30
  18. Malte Buchholz · 3 shared papers, 2012–2025 · strength 0.28
  19. John P. Neoptolemos · 8 shared papers, 2011–2018 · strength 0.28
  20. Clifford C. Nwaeburu · 3 shared papers, 2013–2024 · strength 0.28
  21. Eduard Ryschich · 3 shared papers, 2014–2024 · strength 0.28
  22. Christoph Roesli · 2 shared papers, 2016–2026 · strength 0.27
  23. Elisa M. Noll · 2 shared papers, 2016–2026 · strength 0.27
  24. Martin Ronald Sprick · 2 shared papers, 2016–2026 · strength 0.27
  25. Andreas Trumpp · 2 shared papers, 2016–2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.